Additionally, other bile acid-based therapies that are currently under development are GPBAR1 agonists for promoting cholangiocytes and immune homeostasis in the liver and intestine, which might be of utility in PSC-IBD. The gene discussed is GPBAR1; the disease is inflammatory bowel disease.